Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06416865

Efficacy and Safety of AJU-C52 in Essential Hypertension Patients

A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of AJU-C52 in Compared With C52R1M for Essential Hypertension Patients in Inappropriately Controlled on C52R1L Treatment

Sponsor: AJU Pharm Co., Ltd.

Conditions Essential Hypertension

Interventions AJU-C52L, AJU-C52 C52R1L, C52R1M

Updated 4 times since 2024 Last updated: May 20, 2024 Started: Jun 27, 2022 Primary completion: Dec 12, 2022 Completion: Aug 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Essential Hypertension and is currently actively recruiting participants. AJU Pharm Co., Ltd. leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Recruiting PHASE3
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE3

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AJU Pharm Co., Ltd.

Data source: AJU Pharm Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea